Celladon reports failure of Mydicar gene therapy during trial

April 26, 2015 8:50 PM

3 0

Celladon reports failure of Mydicar gene therapy during trial

Celladon Corporation’s heart failure gene therapy Mydicar has failed during the phase 2b CUPID2 trial. The experimental treatment could not meet the primary and secondary endpoints in the cases of advanced heart failure.

Last year, FDA had awarded ‘breakthrough’ and ‘fast-track’ status to Celladon’s Mydicar. The gene therapy involved injecting a functioning copy of SERCA2a gene into heart cells to improve heart health and to improve pumping power of heart. Mydicar is a virus designed to deliver a gene that reconstit...

Read more

To category page

Loading...